Extract

This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.

Inclusion criteria

• Moderate to severe plaque-type psoriasis

Country

• Argentina
• Canada
• Colombia
• Estonia
• Iceland
• Israel
• Japan
• Latvia
• Lithuania
• Mexico
• Taiwan, Province of China
• United States

Links

• ictrp
• nct